Non-vitamin K oral anticoagulants (NOACs) are the first choice for prophylaxis of
cardioembolism in patients with non-valvular atrial fibrillation (AF) who are anticoagulant …

OBJECTIVE To assess the risk of major adverse cardiovascular events (MACE), all-cause
mortality, and initiation of medical treatment in subjects with prediabetes according to first …

Background: The comparative effectiveness of non-vitamin K antagonist oral anticoagulants
(NOACs) is uncertain, as they have not been compared directly in randomized trials …

The management of antithrombotic therapy for thromboprophylaxis in patients with atrial
fibrillation (AF) has been recently evolved by the progressive replacement of vitamin K …

Background Previous studies examining the use of direct oral anticoagulants (DOACs) in
atrial fibrillation (AF) have largely focused on patients newly initiating therapy. Little is known …

Quality of warfarin therapy in patients with a mechanical prosthetic heart valve (MPHV) has
been barely investigated. We analysed determinants of low time in the therapeutic range …

Introduction Oral anticoagulation (OAC) is indicated for patients with atrial fibrillation (AF)
and atrial flutter (AFL) with a CHA 2 DS 2-VASc score≥ 2 for men and≥ 3 for women. This …

Polypharmacy, intended as the concomitant intake of five or more drugs, 1 is commonly
reported in the general population and particularly among older individuals. 2 Importantly …

Background Multiple registries have reported that> 40% of high-risk atrial fibrillation patients
are not taking oral anticoagulants. The purpose of our study was to determine the presence …

In an era of non-vitamin K antagonist (VKA) oral anticoagulants, there has been relatively
little research focused on redefining current warfarin management services. Warfarin has …